GLOBAL BIOREACTORS MARKET SET TO GROW TO $1.6BN BY 2024, SAYS VISIONGAIN REPORT.

Visiongain’ has launched a new pharma report Global Bioreactors Market 2019-2029:
5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users.

The biopharmaceutical contract manufacturing market has significantly expanded over the past years. The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs.

Factors driving the bioreactors market growth include massive use of hybrid technologies, rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. However, regulatory challenges pertaining to single-use bioreactors and issues concerning leachable and extractable linked to single-use bags are some of the factors hampering the growth of bioreactors market.

For free sample pages on this report please click on:
https://www.visiongain.com/report/global-bioreactors-market-2019-2029/

The lead analyst of the report commented “There has been an unprecedented growth in the biologics and biosimilars market over the past years and these markets are likely to grow at double digit growth rate in the future years.

Therefore, owing to the expectations for robust growth in the biologic drugs demand, large number of manufacturers, including branded and biosimilar drug producers, are increasingly investing in the setting-up of new production facilities.”

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

Leading companies featured in the report include Applikon Biotechnology Inc. (U.S.), BBI-Biotech GmbH (Germany), Bioengineering AG (Switzerland), Danaher Corporation (U.S), Eppendorf AG (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Solaris Biotech (Italy), Thermo Fisher Scientific, Inc. (U.S.)

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

For more pharma reports please visit https://www.visiongain.com/industries/pharma/

Related reports:
• Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018
(https://www.visiongain.com/report/pharma-leader-series-top-50-pharmaceutical-contract-manufacturing-organisations-cmos-market-2018/)
• Global Vaccine Contract Manufacturing Market Report 2018-2028 (https://www.visiongain.com/report/global-vaccine-contract-manufacturing-market-report-2018-2028/)
• Pharmaceutical Contract Manufacturing Market 2018-2028
(https://www.visiongain.com/report/pharmaceutical-contract-manufacturing-market-2018-2028/)
• Top 20 Vaccines Manufacturers 2019
(https://www.visiongain.com/report/top-20-vaccines-manufacturers-2019/)

Visiongain is one of the fastest-growing and most innovative independent business intelligence providers in Europe.
Based in London, UK, Visiongain publishes independent and insightful market reports across a wide range of industry verticals, including automotive, chemical, cyber, defence, energy, pharmaceutical, materials and many more sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. The company has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original business intelligence to depend upon.
https://www.visiongain.com/

Suite 143, Airport House Purley Way, Croydon CR0 0XZ

This release was published on openPR.